Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow FATE by emailGet an email when FATE pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about FATE, unsubscribe in one click. Privacy
📣 What FATE Says Is Next
in 2028 · “Trial design informed by feedback received from FDA RMAT meeting RECLAIM-LN potentially registrational trial to be initiated in 2H 2026 with BLA submission targeted in 2028 1. https://clinicaltrials.gov/study/NCT07570862 (ClinicalTrials.gov) RMAT: FDA Regenerative Medicine Advanced Therapy; 2.”
Company press release, Jun 4, 2026 · SEC filing
2H2026 · “Total enrollment of 53 patients with anticipated commencement of patient dosing in 2H2026; CDRP program acceptance by the FDA aims enrollment expected to complete within 15 months following trial commencement to facilitate the expedited development of”
Company press release, Jun 4, 2026 · SEC filing
second half of 2026 · “The Company expects to provide additional clinical data updates in the second half of 2026.”
Company press release, Feb 26, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full FATE picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for FATE and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.